- Conditions
- Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
- Interventions
- PDS0101, M7824, NHS-IL12
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 3,618
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Surgery, Colorectal Neoplasms, Colitis, Ulcerative, Diverticulitis, Colonic Polyps
- Interventions
- Not listed
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Metastatic Carcinoma in the Liver, Stage IV Colorectal Cancer
- Interventions
- Biomarker Analysis, Cytology Specimen Collection Procedure
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 6
- States / cities
- La Jolla, California • Los Angeles, California • Newport Beach, California + 1 more
- Conditions
- Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- epoetin alfa, placebo
- Biological · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2010
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 17 more
- Conditions
- Breast Cancer, Lung Cancer, Esophageal Cancer, Colon Cancer, Pancreatic Cancer, Liver Cancer, Renal Cancer, Bladder Cancer, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer
- Interventions
- Pillars4Life
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Rectal Cancer
- Interventions
- Not listed
- Lead sponsor
- Power Life Sciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
- Interventions
- Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), FOLFOX, CAPOX, FOLFIRINOX, TAS 102, Bevacizumab, Gemcitabine Combined With Cisplatin, NALIRIFOX
- Drug
- Lead sponsor
- Phanes Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 11
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 8 more
- Conditions
- Colorectal Carcinoma (CRC), Endometrial Carcinoma (EC)
- Interventions
- TPST-1495
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8
- Interventions
- Linaclotide, Placebo
- Drug · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- Rectal Neoplasms
- Interventions
- Pembrolizumab, External beam radiation, Capecitabine
- Drug · Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- gemcitabine hydrochloride, carboplatin, dexamethasone, rituximab
- Drug · Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Colorectal Cancer, Familial Adenomatous Polyposis
- Interventions
- Celecoxib, Placebo, eflornithine, Laboratory biomarker analysis, Questionnaire administration
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- alvocidib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Colon Cancer, Rectal Cancer
- Interventions
- Ramucirumab, Icrucumab, mFOLFOX-6
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Columbia, South Carolina • Nashville, Tennessee
- Conditions
- Pancreatic Cancer, Gastrointestinal Neoplasms, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer, Gall Bladder Cancer, Gastric (Stomach) Cancer, Gastrooesophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatobiliary Neoplasm, Liver Carcinoma, Gallbladder Carcinoma, Bile Duct Carcinoma, Carcinoma of the Large Intestine, Anal Cancer
- Interventions
- Observation
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Stage II Rectal Cancer, Organ Preservation, Non-operative Treatment, Rectal Cancer (Stage III), Rectal Cancer Patients
- Interventions
- Complete responders and Non-complete responders, Chemoradiation + EBRT Boost, Chemoradiation + HDRBT Boost
- Procedure · Radiation
- Lead sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Colorectal Adenoma, Colorectal Cancer (CRC), Colorectal Cancer (CRC) Screening
- Interventions
- colorectal cancer (CRC) screening, colorectal cancer screening, Colonoscopy after bowel cleansing
- Device · Diagnostic Test · Procedure
- Lead sponsor
- Jubaan Ltd.
- Industry
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer, Triple Negative Breast Cancer (TNBC), Renal Cell Carcinoma (Kidney Cancer), Head and Neck Squamous Cell Carcinoma HNSCC
- Interventions
- Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
- Other · Diagnostic Test
- Lead sponsor
- A2 Biotherapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more
- Conditions
- Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
- Interventions
- Trastuzumab deruxtecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 12
- States / cities
- Duarte, California • Santa Rosa, California • Chicago, Illinois + 8 more
- Conditions
- Ulcerative Colitis
- Interventions
- MMX Mesalamine/Mesalazine (Low Dose), MMX Mesalamine/Mesalazine (High Dose)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 9
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Newton, Massachusetts + 5 more
- Conditions
- Diverticulitis, Colon Polyps, Colorectal Cancer
- Interventions
- Not listed
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Colorectal Cancer
- Interventions
- Acetylsalicylic acid (Aspirin), Sulindac, Ursodiol, Sulindac Placebo
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer, Pancreas Cancer
- Interventions
- Dovitinib
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Colorectal Cancer
- Interventions
- Not listed
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 14
- States / cities
- Camden, New Jersey • Edison, New Jersey • Freehold, New Jersey + 10 more